Understand the source comparison
PE-22-28 Dosage Guide: Comparison Across Research Models
The following table summarizes dosage ranges, administration routes, and endpoints from published PE-22-28 research. Use this as a reference for designing your own protocols—but remember that dose-response relationships observed in mice don't always translate
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table summarizes dosage ranges, administration routes, and endpoints from published PE-22-28 research. Use this as a reference for designing your own protocols—but remember that dose-response relationships observed in mice don't always translate linearly to other species or in vitro systems.
- Rodent FST / NSF (Acute)
- 0.5–1mg/kg s.c.
- Subcutaneous injection
- Single dose, 4 hrs
- Immobility time, latency to feed in novel environment
- 0.5mg/kg is the minimum effective dose; 1mg/kg shows no additional benefit, suggesting dose plateau. Ideal for acute mood-related behavioral assays.
- Rodent Neurogenesis (Chronic)
- 0.5mg/kg s.c. daily
- 7–21 days
- BrdU+ and DCX+ cell counts in dentate gyrus
- Repeated daily dosing at 0.5mg/kg produces measurable increases in hippocampal neurogenesis. Consistent with BDNF-mediated plasticity observed in chronic stress models.
- Hippocampal Slice Electrophysiology
- 1–10µM in aCSF
- Bath perfusion
- 10–30 min
- TREK-1 current amplitude, LTP induction
- 1µM saturates TREK-1 channels in slice preparations; 10µM used to confirm maximal blockade. Higher concentrations don't improve receptor occupancy but increase cost per experiment.
- Primary Neuron Culture
- 1–5µM in media
- Direct media addition
- 24–72 hrs
- Neurite outgrowth, synaptic marker expression
- 1–2µM sufficient for promoting neurite extension and synaptogenesis in vitro. Higher concentrations (5µM+) can induce off-target effects in some cell lines.
- In Vivo Microdialysis
- 0.5mg/kg s.c.
- Single dose, 2–6 hrs
- Extracellular serotonin and BDNF in hippocampus
- Demonstrates rapid (2 hr) increase in extracellular BDNF without altering monoamine levels, confirming TREK-1 mechanism distinct from SSRIs.
- Dose selection depends on your experimental question. If you're screening for acute antidepressant-like effects, 0.5mg/kg subcutaneous in mice is the validated starting point. If you're examining chronic neuroplasticity, 0.5mg/kg daily over 14–21 days matches published protocols. For cell culture and slice work, start at 1µM and titrate up only if your endpoint (e.g., TREK-1 current blockade, neurite outgrowth) shows incomplete response.
- One pattern across all models: higher doses don't always improve outcomes. PE-22-28's dose-response curve plateaus around 0.5–1mg/kg in vivo and 1–2µM in vitro. Increasing dose beyond that point increases cost and off-target risk without measurable benefit.